en · de · es
tirzepatide-notes.peptides4088.com › Wiki › �‚¨存处理与检测方法 — Beginner to Advanced

�‚¨存处理与检测方法 — Beginner to Advanced

By Editorial Desk · published 2026-04-04 · last reviewed 2026-05-14 · Wiki

dual agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-05-14 and is reviewed periodically as new material appears.

储存处理与检测方法

溶解操作一般使用注射用水或适宜的水性缓冲液,必要时加入少量助溶剂以改善溶解速度,但应避免剧烈涡旋振荡,因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态,具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分,则取决于用途是否为多次取样。

定量分析的主流方法是反相高效液相色谱联用紫外或质谱检测,利用肽在疏水固定相上的保留行为确定纯度与含量。对于生物基质中的浓度测定,常采用液相色谱串联质谱,并配合固相萃取或蛋白沉淀进行样品前处理。免疫分析法也可使用,但可能受到结构相关肽的交叉反应干扰。

Background And Receptor Pharmacology

Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.

Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.

Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.

Tirzepatide at a glance

PropertyValueNotes
储存温度2 至 8 摄氏度固体粉末,避光密封
外观白色至类白色冻干粉溶解后为澄清至微乳光
溶解性易溶于水性缓冲液避免剧烈振荡
常规纯度方法反相高效液相色谱紫外或质谱检测
定量方法液相色谱串联质谱配合固相萃取前处理

Molecular Background and Dual Receptor Action

Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.

Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.

Related pages on this site

Storage Stability and Analytical Methods

As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.

Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.

Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.

Peptide Structure and Receptor Pharmacology

The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.

Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.

Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.

Tirzepatide 分子背景与靶点

脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强,从而延长循环半衰期,支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征,减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用,属于既定的药代动力学策略。

该化合物的名称与结构由国际非专利名称体系统一维持,不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。

Notes from published material

=== Pro-101-1 (thermal burns) === Pro-101-1 is a topical PDGF-BB gel candidate for the treatment of thermal burns. The company received approval from China's National Medical Products Administration (NMPA) to commence Phase IIa clinical trials in June 2022, which were completed in May 2023. The Phase IIb clinical trial reached last patient out in April 2025, and the clinical report for deep second-degree burns was finalised in December 2025. As of May 2026, Pro-101-1 had enrolled the first patient in its Phase IIIa clinical trial for deep second-degree burns in China. The U.S. FDA has confirmed that Pro-101-1 is eligible for approval via the Section 351(a) biologics BLA pathway.

Outer space has very low density and pressure, and is the closest physical approximation of a perfect vacuum. But no vacuum is truly perfect, not even in interstellar space, where there are still a few hydrogen atoms per cubic meter. Stars, planets, and moons keep their atmospheres by gravitational attraction, and as such, atmospheres have no clearly delineated boundary: the density of atmospheric gas simply decreases with distance from the object. The Earth's atmospheric pressure drops to about 32 millipascals (4.6×10−6 psi) at 100 kilometres (62 mi) of altitude, the Kármán line, which is a common definition of the boundary with outer space. Beyond this line, isotropic gas pressure rapidly becomes insignificant when compared to radiation pressure from the Sun and the dynamic pressure of the solar winds, so the definition of pressure becomes difficult to interpret. The thermosphere in this range has large gradients of pressure, temperature and composition, and varies greatly due to space weather. Astrophysicists prefer to use number density to describe these environments, in units of particles per cubic centimetre. But although it meets the definition of outer space, the atmospheric density within the first few hundred kilometers above the Kármán line is still sufficient to produce significant drag on satellites. Most artificial satellites operate in this region, called low Earth orbit, and must fire their engines every couple of weeks or a few times a year (depending on solar activity).

Neanderthals manufactured Middle Palaeolithic stone tools, and are associated with the Mousterian industry, specifically the Levallois technique. After developing this technology from the Acheulean industry, there is a 150,000 year stagnation in Neanderthal stone tool innovation. Stalled technological growth may have followed from their low population, impeding complex ideas from being spread across their range or passed down generationally. Neanderthals normally collected raw materials from a nearby source, no more than 5 km (3.1 mi). Some communities were also making tools from shells and bone. They may have hafted tips onto spears using birch bark tar. European populations had also been manufacturing wood spears, namely the 400,000 year old British Clacton Spear; 300,000 year old German Schöningen spears; and 120,000 year old German Lehringen Spear, including both likely thrown (Schöningen) and thrusting (Lehringen) types. It has been suggested that Neanderthals likely specifically selected particular wood types (such as European yew in the case of the Clacton and Lehringen spears) for manufacturing spears for their beneficial material properties. Neanderthals invented the earliest dry distillation process to produce birch tar, a substance with adhesive and medicinal properties. A complex underground apparatus was used to distill birch tar from masses of bark, which suggests that a high degree of cultural innovation and evolution took place in the European Middle Paleolithic period.

Sources: en.wikipedia.org

Background from the literature

Similarly, 1,3-dibromopropane reacts with sodium cyanide to form glutaronitrile, and 1-iodooctane reacts with potassium cyanide to give nonannitrile. Cyanations can also be carried out using hydrogen cyanide in combination with triethylaluminum or with diethylaluminum cyanide; for example, in the ring opening of an epoxide to a β-cyanohydrin or in the 1,4-addition of cyanide to an enone. Trimethylsilylcyanide is another cyanating reagent capable of opening epoxides to β-cyanohydrins, with concomitant silylation of the oxygen atom. Trimethylsilyl cyanide also enables substitution of tertiary alkyl halides, which is not feasible under Kolbe nitrile synthesis conditions. In the presence of suitable transition metal catalysts, hydrocyanation allows addition of hydrogen cyanide to the multiple bonds of alkenes and alkynes to afford nitriles. Nickel catalysts are typically employed. Direct handling of hydrogen cyanide is often unnecessary, as synthetic equivalents such as acetone cyanohydrin or isovaleronitrile may be used. An important industrial process is the hydrocyanation of butadiene to adiponitrile.

Yeast hulls (or Yeast ghosts) are the remnants of yeast cell walls left over from the commercial production of yeast strains to be used for inoculation. In addition to providing a source of assimilable nitrogen from amino acids, they also provide lipids and sterols that can be used by the cells to strengthen their plasma membrane, allowing for the uptake of other sources of nitrogen.

Committee on Herbal Medicinal Products (HMPC) (22 May 2012). "Assessment report on Citrus bergamia Risso et Poiteau, aetheroleum Final" (PDF). European Medicines Agency (EMA). Archived from the original (PDF) on 8 April 2014. Retrieved 7 April 2014. Committee on Herbal Medicinal Products (HMPC) (22 May 2012). "List of references supporting the assessment of Citrus bergamia Risso et Poiteau, aetheroleum Final" (PDF). European Medicines Agency (EMA). Archived from the original (PDF) on 8 April 2014. Retrieved 7 April 2014.

Traditionally, solid-phase synthesis has relied on polystyrene-based resins for the synthesis of all kinds of peptides. However, due to their high hydrophobicity, these resins have certain limitations, particularly in the synthesis of complex peptides, and in such cases, polyethylene glycol (PEG)-based resins are often found to give superior results. Another powerful strategy for expediting the assembly of complex peptides is to employ pseudoproline dipeptides. These derivatives disrupt the interactions among chains that are usually the cause of poor coupling yields in aggregated sequences. A large arsenal of chemical tools is now available for the synthesis of almost all peptides up to 40 amino acid residues. However, several small-size peptides and many large peptides and/or proteins are still unavailable by classical methods.

Sources: en.wikipedia.org

Frequently asked questions

固体粉末应如何存放?

建议在低温、避光、干燥环境中密封保存,常见条件为 2 至 8 摄氏度,长期存放可置于更低温度。应避免反复冻融,并尽量减少容器开启次数。

溶解后能保存多久?

溶解后的稳定时间通常短于固体形态,受浓度、缓冲液和容器材质影响。冷藏条件下一般只能维持较短时间,具体期限应通过实际稳定性实验确认。

常用哪些分析手段?

反相高效液相色谱用于纯度与含量测定,液相色谱串联质谱用于生物基质中的定量,体积排阻色谱用于检测聚集体。多种方法结合才能较完整地表征样品。

What is tirzepatide?

It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.

Network